Clinical trials: Immune System Diseases
Rheumatoid Arthritis
Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis
This study was intended to assess the safety, efficacy, and response to treatment using the American College of Rheumatology (ACR) criteria of 20% improvement in symptoms (ACR20) and to investigate a potential biomarker profile…
- Trial name
- NCT00504595
- Testing
- ACZ885 (investigational)
- Where
- 4 sites in Russia, Spain and 2 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novartis
Chronic Graft Versus Host Disease
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Participants will be randomized 1:1 to receive either belumosudil or Best Available Therapy (BAT), with stratification based on baseline cGVHD severity as defined by the 2014◦NIH consensus criteria (moderate versus severe), use…
- Trial name
- NCT07771439
- Testing
- Belumosudil, Best available therapy (BAT)
- Volunteers
- 356 people
- Sponsor
- Sanofi
Bronchial Asthma
Asthma During Pregnancy; Impact of Severity
bronchial asthma (BA) may affect pregnancy and this affection may increase with increasing asthma severity. This study was designed to detect the effect of asthma severity on the course of asthma during pregnancy and its effect…
- Trial name
- NCT05180877
- Where
- Egypt
- Volunteers
- 137 people
- Sponsor
- Sohag University
Multiple Sclerosis, Vitamin D Deficiency
Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis
The purpose of this study is to determine the safety and the immunologic effects of supplementation with low-dose and high-dose cholecalciferol (vitamin D3) in patients with multiple sclerosis.
- Trial name
- NCT01024777
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Primary Myelofibrosis, Myeloproliferative Disorders
PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis
A number of groups have demonstrated very low incidence of acute and chronic graft-versus-host disease (GVHD) with post-transplantation cyclophosphamide (PTCy) in haploidentical and unrelated allogeneic stem cell transplantation…
- Trial name
- NCT02806375
- Testing
- Allogeneic hematopoietic stem cell transplantation, Busulfan, Fludarabine monophosphate
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Multiple Myeloma, Newly Diagnosed
Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients
This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.
- Trial name
- NCT06758375
- Testing
- Low-dose teclistamab
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
This phase I/II trial studies the best dose and side effects of venetoclax and how well it works in combination with ixazomib and dexamethasone in treating patients with t(11;14) negative multiple myeloma that has come back or…
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, t(11;14) Negative
- Trial name
- NCT03856112
- Testing
- Dexamethasone, Ixazomib, Ixazomib Citrate
- Sponsor
- National Cancer Institute (NCI)
Food Allergy
The Basophil Activation Test For Egg Allergy
In this study, basophil activation test (BAT) established by the investigators' lab was evaluated for its sensitivity and specificity in child egg allergy diagnosis.
- Trial name
- BAT (NCT06559319)
- Testing
- blood sampling
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Xia Peng
Lymphoma, Indolent Non-hodgkin Lymphoma
MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
This is a phase II pilot, single arm, open label study designed to assess the efficacy, safety, and feasibility of MRD adapted duration of BR for untreated or R/R iNHL.
- Trial name
- NCT06557330
- Testing
- Bendamustine, Rituximab
- Volunteers
- 24 people
- Sponsor
- Fox Chase Cancer Center
Asthma
Effectiveness of the Propeller Health (Formerly Asthmapolis) Monitoring System
Propeller Health is collaborating with Dignity Health (formerly Catholic Healthcare West (CHW)) to carry out a focused demonstration project to evaluate the effectiveness and potential cost savings of a deployment of the…
- Trial name
- NCT01509183
- Testing
- Propeller Health System (formerly Asthmapolis System)
- Where
- United States
- Volunteers
- 495 people
- Sponsor
- Reciprocal Labs
Diffuse Large B-cell Lymphoma
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, accounting for 35% of lymphoma. Chimeric antigen receptor T cell (CAR-T) therapy is a new method to treat DLBCL.
- Trial name
- CICPD (NCT04381741)
- Testing
- CD19-7×19 CAR-T plus PD1 monoclonal antibody
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diffuse Large B-cell Lymphoma, de Novo DLBCL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
The purpose of this study is to evaluate the efficacy of Pixantrone + Rituximab compared to Gemcitabine + Rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or follicular grade 3 lymphoma.
- Conditions
- Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma, Follicular Grade 3 Lymphoma
- Trial name
- PIX-R (NCT01321541)
- Testing
- Pixantrone + Rituximab, Gemcitabine + Rituximab
- Where
- 131 sites in United States, Austria and 15 more
- Volunteers
- 312 people
- Sponsor
- CTI BioPharma
HIV/AIDS, Infant Morbidity
Assessing the Feasibility, Acceptability and Effects Of HIV Birth Testing In Maternity Settings In Zimbabwe
This study aims to assess the feasibility and, acceptability and effects of implementing HIV testing at birth testing using point-of-care (POC) HIV nucleic acid testing (NAT) in maternity settings.
- Conditions
- HIV/AIDS, Infant Morbidity, Perinatal HIV Infection, HIV Infections
- Trial name
- NCT04206241
- Testing
- Point of care early infant diagnosis (POC EID)
- Where
- 10 sites in Zimbabwe
- Volunteers
- 278,833 people, healthy volunteers welcome
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
Bronchiolitis Obliterans, Graft Vs Host Disease
The Safety and Tolerability of Pirfenidone for BOS After HCT
This is a phase 1, non-randomized, single-arm, open label, single center clinical trial to determine the tolerability and safety of pirfenidone in patients with BOS associated with lung GVHD after hematopoietic cell transplant.
- Trial name
- STOP-BOS (NCT03315741)
- Testing
- Pirfenidone 267 MG [Esbriet]
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Leukemia
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004905
- Testing
- filgrastim, recombinant interferon alfa, cyclophosphamide
- Where
- 3 sites in United States
- Sponsor
- Loyola University
Multiple Myeloma, Chronic Lymphocytic Leukemia
Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCT
The purpose of this study is to test the effectiveness of evidence-informed mobile apps, Myeloma Coach and CLL Coach. These apps have been developed to help manage the physical and emotional symptoms experienced by multiple…
- Trial name
- NCT05928156
- Testing
- Myeloma Coach or CLL Coach Mobile App, Springboard Beyond Cancer informational website
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Duke University
Amyloid Light Chain (AL) Amyloidosis
Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis
Amyloid light chain (AL) amyloidosis is a rare disease caused by abnormal plasma cells producing misfolded light chain proteins that deposit in organs, leading to organ dysfunction and failure.
- Trial name
- NCT07793422
- Testing
- Etentamig, Daratumumab, Cyclophosphamide
- Volunteers
- 370 people
- Sponsor
- AbbVie
Relapsed Refractory Multiple Myeloma (RRMM)
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
This study will evaluate efficacy and tolerability various doses of belantamab mafodotin in combination with cevostamab and pomalidomide in patients with multiple myeloma who have relapsed disease after two or more lines of…
- Trial name
- NCT07831122
- Testing
- Belamaf, Cevostamab, Pomalidomide
- Where
- 7 sites in Canada
- Volunteers
- 108 people
- Sponsor
- Canadian Myeloma Research Group
Smoldering Multiple Myeloma
PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
This study is evaluating a new vaccine against PD-L1 as a possible treatment for high-risk smoldering multiple myeloma.
- Trial name
- NCT03850522
- Testing
- PD-L1 peptide
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Lene Meldgaard Knudsen
Allergic Contact Dermatitis
Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation
The current knowledge of the pathophysiology of allergic contact dermatitis is based on the murine model. In this model, CD8+ T cells are effector cells, and CD4+ T cells regulate the response by limiting the expansion of CD8+ T…
- Trial name
- NCT00445029
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon